Arbutus, Roivant further existing RNA deal through formation of Genevant JV
Executive Summary
Continuing a relationship that began last year, Arbutus Biopharma Corp. and Roivant Sciences GMBH entered a new agreement in which they aim to further the efforts of their hepatitis B virus (HBV) partnership by forming an equally owned joint venture called Genevant Sciences Ltd., to develop RNA-based drugs in other therapeutic areas.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Liposomes
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Joint Venture
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice